{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014355","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.390501+00:00","generated_at":"2026-06-04T00:04:58.846414+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment","bullets":["10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.","GraftAssure RUO launch expected Q2 2024 at select US/EU transplant centers, broader rollout H2 2024.","Bio-Rad gets exclusive global distribution rights outside US/Germany; option for IVD rights upon FDA clearance with second equity investment.","Transplant monitoring market estimated over $1B with 157K annual transplants and 9.1% growth.","Bio-Rad makes initial equity investment in Oncocyte; specific amount not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014355","json":"https://secwatch.observer/filing/0001493152-24-014355.json","markdown":"https://secwatch.observer/filing/0001493152-24-014355.md","text":"https://secwatch.observer/filing/0001493152-24-014355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:04:58.846414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02949f90ae1f24965f29b95aa20b483af3ed7d98","claim":"Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Bio-Rad Laboratories, Inc."},{"label":"Effective","value":"2024-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}